145 results
Page 4 of 8
424B5
e11d 7l24442n
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
32jvlo6t7jugkwy
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
u7xj7 w7ozv6ykkq
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
ict328ys40q2ns
6 Nov 19
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
7:35am
8-K
EX-99.1
mu7yybyk
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-10.1
8f4 s9igj
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
sg5ynoyqp r4
25 Jul 19
Other Events
8:07am
8-K
EX-99.1
0m6rshp
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
4fzib0gkf1k4
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
pgfzb24nb59sc ymtjv
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
8-K
EX-99.1
2mwrqkc0hwrg wib
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
61s66cq9zs2
2 Apr 19
Other Events
8:10am
8-K
EX-99.1
i9vv 386v4
2 Apr 19
Other Events
8:10am